Your browser doesn't support javascript.
loading
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll, Thomas M; Chadwick, Joseph A; Owen, Richard P; White, Michael J; Kaplinsky, Joseph; Peneva, Iliana; Frangou, Anna; Xie, Phil F; Chang, Jaeho; Roth, Andrew; Amess, Bob; James, Sabrina A; Rei, Margarida; Fuchs, Hannah S; McCann, Katy J; Omiyale, Ayo O; Jacobs, Brittany-Amber; Lord, Simon R; Norris-Bulpitt, Stewart; Dobbie, Sam T; Griffiths, Lucinda; Ramirez, Kristen Aufiero; Ricciardi, Toni; Macri, Mary J; Ryan, Aileen; Venhaus, Ralph R; Van den Eynde, Benoit J; Karydis, Ioannis; Schuster-Böckler, Benjamin; Middleton, Mark R; Lu, Xin.
Afiliação
  • Carroll TM; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Chadwick JA; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Owen RP; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • White MJ; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Kaplinsky J; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Peneva I; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Frangou A; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK.
  • Xie PF; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Chang J; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Roth A; Department of Pathology and Molecular Medicine, University of British Columbia, Vancouver, Canada; Department of Computer Science, University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, BC Cancer, Vancouver, Canada.
  • Amess B; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • James SA; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Rei M; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Fuchs HS; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • McCann KJ; Cancer Research UK Southampton Experimental Cancer Medicine Centre, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Omiyale AO; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Jacobs BA; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Lord SR; Department of Oncology, University of Oxford, Oxford, UK.
  • Norris-Bulpitt S; Early Phase Clinical Trials Unit, Cancer & Haematology Centre, Churchill Hospital, Oxford, UK.
  • Dobbie ST; Oncology Clinical Trials Office (OCTO), Department of Oncology, University of Oxford, Oxford, UK.
  • Griffiths L; Oncology Clinical Trials Office (OCTO), Department of Oncology, University of Oxford, Oxford, UK.
  • Ramirez KA; Ludwig Cancer Research, New York, NY, USA.
  • Ricciardi T; Ludwig Cancer Research, New York, NY, USA.
  • Macri MJ; Ludwig Cancer Research, New York, NY, USA.
  • Ryan A; Ludwig Cancer Research, New York, NY, USA.
  • Venhaus RR; Ludwig Cancer Research, New York, NY, USA.
  • Van den Eynde BJ; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK; Ludwig Institute for Cancer Research, Brussels, Belgium; de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.
  • Karydis I; Cancer Sciences Unit, University of Southampton and Cancer Care Group, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
  • Schuster-Böckler B; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK.
  • Middleton MR; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK; Department of Oncology, University of Oxford, Oxford, UK; Early Phase Clinical Trials Unit, Cancer & Haematology Centre, Churchill Hospital, Oxford, UK. Electronic addre
  • Lu X; Ludwig Institute for Cancer Research, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK. Electronic address: xin.lu@ludwig.ox.ac.uk.
Cancer Cell ; 41(7): 1222-1241.e7, 2023 07 10.
Article em En | MEDLINE | ID: mdl-37433281
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article